title: Management of the Patient with Aggressive and Resistant Papillary Thyroid Carcinoma.
abstract: OBJECTIVE
  Papillary carcinoma is the most frequent type of thyroid cancer and was considered the most benign of all thyroid carcinomas, with a low risk of distant metastases. However, there are some variants of papillary thyroid carcinoma that have affinity to spread in many organs, such as: lymph nodes, lungs and bones.
  
  
  OBJECTIVE
  The aim of this study was presentation of a case with papillary carcinoma of the thyroid gland, very persistent and resistant in treatment with I 131.
  
  
  RESULTS
  A man 56 years old were diagnosed with papillary carcinoma of thyroid gland. He underwent a surgical removal of the tumor and right lobe of thyroid gland. With histopathology examination, were confirmed follicular variant of papillary carcinoma pT4. Two weeks later he underwent total thyroidectomy and was treated with 100 mCi of J 131. Six months later, the value of thyroglobulin was found elevated above upper measured limits (more than 500 ng/ml). Patient underwent surgical removal of 10 metastatic lymph nodes in the left side of the neck and has been treated with 145 mCi of radioiodine I 131. The examination after 5 months shows elevation of thyroglobulin, more than 20000 ng/ml and focally uptake of J 131 in the left lung. Patient was treated once again with 150 mCi radioiodine J 131. Whole body scintigraphy was registered focal uptake of radioiodine in the middle of the left collarbone. After a month, patient refers the enlargement of the lymph node in the right side of the neck. Currently patient is being treated with kinase inhibitor drug sorafenib and ibandronate. We have identified first positive response in treatment. Enlarged lymph node in the neck was reduced and the patient began feeling better.
  
  
  CONCLUSIONS
  This study suggests that some subtypes of papillary thyroid carcinoma appear to have more aggressive biological course. Subtypes of papillary thyroid carcinoma such as diffuse sclerosing carcinoma, tall cell or columnar cell and insular variants, appears to have more aggressive biological course and need early detection and other kind of treatment.
authors.affiliation: Department of Nuclear Medicine, University Clinical Center of Kosova, Pristine, Kosovo.
authors.forename: Rame
authors.initials: R
authors.lastname: Miftari
authors.affiliation: Department of Biochemistry, University Clinical Center of Kosova, Pristine, Kosovo.
authors.forename: Valdete
authors.initials: V
authors.lastname: Topçiu
authors.affiliation: Department of Sports Medicine, University Clinical Center of Kosova, Pristine, Kosovo.
authors.forename: Adem
authors.initials: A
authors.lastname: Nura
authors.affiliation: Department of Biochemistry, University Clinical Center of Kosova, Pristine, Kosovo.
authors.forename: Valdete
authors.initials: V
authors.lastname: Haxhibeqiri
mesh_terms: D002291:Carcinoma, Papillary / Q000175:diagnosis* / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077273:Thyroid Cancer, Papillary; D013964:Thyroid Neoplasms / Q000175:diagnosis* / Q000628:therapy*
keywords: papillary thyroid cancer (PTC); radioiodine (J131); sorafenib